[Effect of a C-type CpG ODN on CVB3-infected mice].
OBJECTIVE
To investigate the potential effect of a self-designed C-type CpG ODN (D-SL01) on coxsackie virus B3 (CVB3) infection.


METHODS
HeLa cells infected by CVB3 were used as cell a model and BALB/c mice inoculated with CVB3 were used as an animal model for evaluating the anti-viral effect of D-SL01.


RESULTS
The supernatants of D-SL01-treated PBMC protected HeLa cells from CVB3 infection and Vero E6 cells from VSV infection. However, in vivo study showed that D-SL01 reduced the body weight of CVB3-infected mice and aggravated the pathological changes related to myocarditis in mice when they were intraperitonealy injected for 6 days in succession.


CONCLUSIONS
When used for the treatment of viral-infected diseases in vivo, CpG ODN may function in a complicated way, which indicates its administration time, route and dosage, should be taken into full consideration.
Yang
Liang
L
Department of Molecular Biology, Norman Bethune Medical College, Jilin University, Changchun, China. yangliang_811212@yahoo.com.cn
Sun
Wan-qing
WQ
Wang
Li
L
Wang
Xiu-li
XL
Wan
Min
M
Yu
Yong-li
YL
Wang
Li-ying
LY
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002460:Cell Line; D002522:Chlorocebus aethiops; D003384:Coxsackievirus Infections / Q000188:drug therapy* / Q000821:virology; D029822:Enterovirus B, Human / Q000187:drug effects* / Q000502:physiology*; D006367:HeLa Cells; D006801:Humans; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D009205:Myocarditis / Q000188:drug therapy / Q000821:virology; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D014709:Vero Cells
D000998:Antiviral Agents; D009838:Oligodeoxyribonucleotides